Stay updated on GO-2 Study RVT-1401 in Graves' Ophthalmopathy Clinical Trial

Sign up to get notified when there's something new on the GO-2 Study RVT-1401 in Graves' Ophthalmopathy Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the GO-2 Study RVT-1401 in Graves' Ophthalmopathy Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-13T21:28:17.000Z thumbnail image
  4. Check
    4 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    10 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the efficacy and safety/tolerability assessment of three dose regimens of RVT-1401 in the treatment of active, moderate to severe Graves' Ophthalmopathy participants.
    Difference
    0.1%
    Check dated 2024-06-06T14:27:28.000Z thumbnail image
  7. Check
    24 days ago
    Change Detected
    Summary
    The webpage has been updated to include detailed eligibility criteria for participants, specifying that researchers are looking for individuals aged 18 or older with a clinical diagnosis of Graves' disease and active, moderate to severe Graves' Ophthalmopathy. Previously, no information was provided under Participation Criteria.
    Difference
    21%
    Check dated 2024-05-22T21:35:06.000Z thumbnail image
  8. Check
    46 days ago
    Change Detected
    Difference
    1%
    Check dated 2024-04-30T22:48:52.000Z thumbnail image

Stay in the know with updates to GO-2 Study RVT-1401 in Graves' Ophthalmopathy Clinical Trial

Enter your email address, and we'll notify you when there's something new on the GO-2 Study RVT-1401 in Graves' Ophthalmopathy Clinical Trial page.